Country | Czechia | Denmark | Estonia | Finland | Iceland | Italy | Netherlands | Norway | Portugal | Romania | Slovenia | Spain | Sweden | Switzerland | UK |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Registry | ATTRA | DANBIO | ESRBTR | ROB-FIN | ICEBIO | GISEA | AmSpA | NOR-DMARD | Reuma.pt | RRBR | Biorx.si | BIOBADASER | SRQ | SCQM | BSRBR-AS |
General information | |||||||||||||||
Patients included in the registry | |||||||||||||||
AxSpA/PsA patients in the data completeness analyses (n)a | 3512/1331 | 4855/3652 | <100/<100 | 1699/720 | 386/424 | 171/457 | <100/- | 1805/1052 | 1985/1094 | 1325/242 | 616/448 | 1126/1036 | 791/1084b | 1893/1021 | 1091/- |
AxSpA, year of start | 2002 | 2002 | 2013 | 2000 | 2008 | 2010 | 2019 | 2000 | 2009 | 2013 | 2010 | 2000 | 1999 | 2005 | 2012 |
PsA, year of start | 2002 | 2002 | 2013 | 2000 | 2008 | 2010 | - | 2000 | 2009 | 2013 | 2010 | 2000 | 1999 | 2006 | - |
Other rheumatological conditions | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | ||
Additional entry criteria | |||||||||||||||
Treatment with a b/ts DMARD | √ | √ | √ | √ | √ | √ | √ | √ | |||||||
Basis for diagnosis registration | |||||||||||||||
ICD-10 | √ | √ | √ | √ | √ | √ | √ | ||||||||
Expert opinion | √ | √ | √ | √ | √ | √ | √ | ||||||||
ASAS/mNY criteria | √ | √ | √ | √ | √ | √ | √ | √ | √ | ||||||
CASPAR criteria | √ | √ | √ | - | √ | √ | √ | √ | - | ||||||
Number of visits per year | |||||||||||||||
First year | 3 | 3 | 2 | 2-3 | 2 | 2 | 2 | 4 | 3 | 2 | 4 | 1 | 2 | 2 | 3 |
Subsequent years | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 2 | 3 | 2 | 2 | 1 | 2 | 2 | 1 |
Data entry | |||||||||||||||
Electronic | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ |
Paper-based | √ | √ | √ | √ | √ | √ | √ | √ | |||||||
Interactive fields | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | ||||
Medication | |||||||||||||||
b/tsDMARDs | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ |
csDMARDs | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | |
NSAIDs | √ | √ | √ | √ | √ | √ | √ | √ | |||||||
Oral glucocorticoids | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | ||||
Coverage | |||||||||||||||
Geographic area covered by the registry | |||||||||||||||
Nationwide | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | ||||
Estimate of eligible patients included | |||||||||||||||
axSpA | 95 | 95 | 95 | 60 | 95 | 15 | 0.5 | 25 | 10 | 100 | 70 | 5 | 82 | 10 | 0.5 |
PsA | 95 | 85 | 95 | 60 | 95 | 10 | - | 25 | 15 | 100 | 60 | 4 | 76 | 10 | - |
Institutions collecting patient data | |||||||||||||||
Private rheumatology practices | √ | √ | √ | √ | √ | √ | √ | ||||||||
University hospital rheumatology departments | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ |
Other hospital rheumatology departments | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | ||
Funding of registry activities (%) | |||||||||||||||
Research grants | 5 | 80 | 20 | 15 | 50 | 20 | 2 | ||||||||
Public sector | 15 | 100 | 10 | 50 | |||||||||||
Industry | 95 | 85 | 100 | 20 | 80 | 85 | 50 | 80 | 90 | 50 | 90 | 98 | |||
Other | 100c | 100d | 10 |